Authors

Latest:

Ph+ ALL Management Updates: Expert Insights

Leading experts Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss diagnostic challenges, evolving treatments, and prognosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Bijal Shah, MD H. Lee Moffitt Cancer Center & Research Institute

Latest:

The Potential Future Impact of CAR T Cell Therapy in Adult ALL

Experts in hematology oncology consider unmet needs for adult patients with relapsed/refractory ALL and reflect on the potential impact that FDA approval of CAR T cell therapy would have on the treatment landscape.

Bijal Shah, MD, Moffitt Cancer Center

Latest:

Treating Mantle Cell Lymphoma: A Look At ZUMA-2 Trial And KTE-X19

Bilal Piperdi, MD

Latest:

Dr. Piperdi Discusses RICTOR Amplification in Lung Cancer

Bilal Piperdi, MD, discusses an analysis presented at the 2014 ASCO Annual Meeting that looked at RICTOR amplification to define a subset of patients with lung cancer.

Bin Zheng, PhD

Latest:

Bin Zheng on the Potential of Diabetes Drugs in Melanoma

Bin Zheng, PhD, assistant professor of Dermatology at Harvard Medical School and assistant biologist at Massachusetts General Hospital, discusses the potential for phenformin, a drug created for Type 2 diabetes, to be used for patients with melanoma.

Bing Xia, MD

Latest:

Dr. Xia on the Frontline Treatment Landscape of ALK-Positive NSCLC

Bing Xia, MD, assistant professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses the frontline treatment landscape of ALK-positive non–small cell lung cancer (NSCLC).

Binod Dhakal, MD

Latest:

How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD

Drs Dhakal and Baljevic discuss first- and subsequent-line treatment options for patients with multiple myeloma.

Biological Sciences

Biotech News

Latest:

Age Cutoff for Pap Tests Questioned

More than 12% of newly diagnosed cervical cancers occurred in women aged 70 to 85 years during 2000 to 2006

Birte Wistinghausen, MD

Latest:

Dr. Wistinghausen on Developing Drugs for Children With Cancer

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses developing drugs for children with cancer.

Bita Fakhri, MD, MPH

Latest:

Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

The panel concludes its discussion with a look to the future of CLL treatment, focusing on emerging novel agents and exciting clinical research.

BJ Rimel, MD

Latest:

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Drs Camidge and Rimel spotlight Dr Rimel’s career journey and the work she does to expand medical care for transgender patients.

Björn Löppenberg, MD

Latest:

Dr. Loppenberg on Benefits of Local Treatment for Metastatic Prostate Cancer

Bob Asinof

Latest:

Bob Asinof on Recruiting Physicians to Private Centers

Bob Asinof, chief executive officer of The Urology Center of Colorado, discusses the challenges of recruiting urologists to their center while competing with larger cancer centers and hospital systems.

Bob Orzechowski, MBA

Latest:

Managing the Growth of NCODA

Bob Orzechowski, MBA, Lancaster Cancer Center, discusses managing the growth of NCODA.

Bob T. Li, MD, MPH

Latest:

Dr. Li on the Limitations of the IMpower010 Trial in Resected Stage IB-IIIA NSCLC

Bob T. Li, MD, PhD, MPH, discusses the limitations of the phase 3 IMpower010 trial in resected stage IB to IIIA non–small cell lung cancer.

Bob Valamehr, PhD

Latest:

Advantages of Off-the-Shelf CAR NK Therapy in B-Cell Malignancies

Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.

Bobbie J. Rimel, MD

Latest:

Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian Cancer

Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

Bobby Liaw, MD

Latest:

The Case for Platinum Therapy in Prostate Cancer

The arsenal of therapeutic options for men with castration-resistant prostate cancer has steadily grown as ongoing research uncovers more about prostate cancer biology and resistance mechanisms.

Bone Cancer Research